NASDAQ: VERV - Verve Therapeutics, Inc.

Yield per half year: -14.31%
Sector: Healthcare

Share chart Verve Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Verve Therapeutics, Inc., компания по производству генетических лекарств, занимается разработкой препаратов для редактирования генов, предназначенных для пациентов с сердечно-сосудистыми заболеваниями. Его главный кандидат на продукт - VERVE-101, однократное средство для редактирования генов, которое навсегда отключает ген PCSK9 в печени. Компания также участвует в программе разработки ANGPTL3, чтобы навсегда отключить ген ANGPTL3 в печени.

More details
У него есть соглашение о сотрудничестве и лицензионное соглашение с Beam Therapeutics; соглашение о разработке и опционе с Acuitas Therapeutics, Inc .; и лицензионное соглашение Cas9 с The Broad Institute и президентом и научными сотрудниками Гарвардского колледжа. Компания ранее была известна как Endcadia, Inc. и сменила название на Verve Therapeutics, Inc. в январе 2019 года. Verve Therapeutics, Inc. была зарегистрирована в 2018 году и базируется в Кембридже, штат Массачусетс.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

P/BV 4.88
EV/EBITDA -2.37
EBITDA -0.0135
Цена ао 5.69
Число акций ао 0.06418 млрд
Сайт https://www.vervetx.com
Див.доход ао 0
P/E 6.24
Выручка 0.0019
P/S 538.57
ISIN US92539P1012
Валюта usd
IPO date 2021-06-17
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Change price per day: +1.79% (5.59)
Change price per week: +23.7% (4.6)
Change price per month: +5.57% (5.39)
Change price per 3 month: -16.57% (6.82)
Change price per half year: -14.31% (6.64)
Change price per year: -47.99% (10.94)
Change price per 3 year: -84.92% (37.72)
Change price per year to date: -51.49% (11.73)
All parameters

Underestimation

Title Value Grade
P/S 80.83 1
P/BV 1.59 8
P/E 6.24 10
EV/EBITDA -3.76 0
Total: 4.75

Efficiency

Title Value Grade
ROA, % -26.58 0
ROE, % -33.37 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.3441 10
Total: 8.4

Growth impulse

Title Value Grade
Yield Revenue, % 505.77 10
Yield Ebitda, % 1508.07 10
Yield EPS, % 186.01 10
Total: 10
More

Institutions Volume Share, %
Alphabet Inc. 12 14.71
Vanguard Group Inc 6 7.54
ARK Investment Management, LLC 6 7.19
Blackrock Inc. 5 6.4
State Street Corporation 5 6.07
T. Rowe Price Investment Management, Inc. 5 5.45
Federated Hermes, Inc. 4 4.24
FMR, LLC 3 4.02
Casdin Capital, LLC 3 3.64
Nikko Asset Management Americas, Inc. 3 3.09

ETF Share, % Profitability for 1 year, % Dividends, %
Avantis U.S Small Cap Equity ETF 0.04178 27.774101036841 1.68271
Avantis Responsible U.S. Equity ETF 0.00001 26.778312788906 1.45257
Avantis U.S. Equity ETF 0.00043 32.224830464267 1.59151
Virtus LifeSci Biotech Clinical Trials ETF 0.73383 63.040315712071 0.33
ProShares Ultra Nasdaq Biotechnology 0.03074 51.697637072723 0.85651
Dimensional U.S. Targeted Value ETF 0.00402 26.007247921552 1.93487
Dimensional US Core Equity Market ETF 0.00106 30.983243755928 1.40618
Dimensional U.S. Equity ETF 0.00047 31.530984204131 1.3557
Fidelity MSCI Health Care Index ETF 0.00505 13.390080209527 1.46057
Goldman Sachs Innovate Equity ETF 0.04007 29.658020073179 1.20987
Global X Genomics & Biotechnology ETF 0.49685 2.5824964131994 0.15585
ProShares Hedge Replication ETF 0.0024 5.9237999659878 1.47892
Invesco Nasdaq Biotechnology ETF 0.04353 28.578975171685 0.8565
iShares Morningstar Small-Cap ETF 0.00719 30.095066471445 1.60498
iShares Morningstar Small-Cap Growth ETF 0.01448 33.628071953382 0.72598
iShares Micro-Cap ETF 0.09357 36.318555985322 1.54048
iShares Russell 3000 ETF 0.00044 32.57283798366 1.43482
iShares Morningstar Small-Cap ETF 0.00719 391.25300933451 1.60498
iShares Morningstar Small-Cap Growth ETF 0.01448 680.05582339508 0.72598
SPDR S&P Kensho New Economies Composite ETF 0.09643 31.133671742809 0.88486
Direxion Daily S&P Biotech Bull 3x Shares 0.06928 4067.9190751445 0.25924
Nuveen ESG Small-Cap ETF 0.03159 29.971671388102 1.41019
Invesco FTSE RAFI US 1500 Small-Mid ETF 0.00612 35.452103849597 1.75869
Schwab U.S. Small-Cap ETF 0.00902 34.281650071124 1.51433
Schwab U.S. Broad Market ETF 0.00036 32.5 1.43354
SPDR Portfolio MSCI Global Stock Market ETF 0.00532 23.600605143722 2.19607
ProShares UltraPro Russell2000 0.00796 89.821266282945 1.47873
Vanguard Russell 3000 ETF 0 31.87314172448 1.43817
Vanguard Russell 2000 ETF 0.02 35.648084105685 1.48801
WisdomTree BioRevolution Fund 0.44376 15.953112715317 0.78691
Principal Healthcare Innovators ETF 0.04066 618.4964157054 0.8416
Future Tech ETF 0.04066 426.33969118983 0.8416



Head Job title Payment Year of birth
Dr. Sekar Kathiresan M.D. Co-Founder, CEO & Director 899.55k 1972 (52 years)
Mr. Andrew D. Ashe J.D. President, COO & General Counsel 703.85k 1967 (57 years)
Dr. Anthony Philippakis M.D., Ph.D. Co-Founder & Scientific Advisory Board Member 7.97k
Dr. Kiran Musunuru M.D., M.P.H., Ph.D. Co-Founder N/A
Dr. J. Keith Joung M.D., Ph.D. Co-Founder N/A
Dr. Barry S. Ticho FACC, M.D., Ph.D. Co-Founder N/A 1961 (63 years)
Mr. Issi Rozen M.B.A. Co-Founder & Strategic Advisor N/A
Ms. Allison Dorval CFO & Principal Accounting Officer 260.93k 1976 (48 years)
Dr. Troy Lister Ph.D. Chief Scientific Officer
Ms. Joan Nickerson M.B.A. Chief Administrative Officer 1969 (55 years)

Address: United States, Cambridge, MA , 500 Technology Square - open in Google maps, open in Yandex maps
Website: https://www.vervetx.com